The Myths of Biotech Investing

Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing.

Biotech investing differs from tech investing.

There’s often no revenue traction to assess.

The startup must navigate the FDA path while dealing with cutting-edge devices and therapeutics.

Here are some myths of biotech investing:

Myth 1-Biotech startups are building companies.

In many cases, the biotech startup will sell during the clinical trials or at FDA approval.

They rarely proceed to launching a business.

Myth 2- Biotechs take much longer than tech companies to exit.

Most biotech startups exit in the 3 to 5 year range, which is often shorter than tech companies.

Myth 3- Regulatory is the key hurdle to overcome.

In reality, it’s proving the therapeutic works.

Most drugs fail in clinical trials and never reach FDA submission.

Myth 4-Reimbursement is the key to a successful biotech therapy.

In reality, it’s showing value to the physician and patient through high efficacy and low toxicity, which is the key to success.

Consider these myths in analyzing biotech startups for investment.

Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding.

Let’s go startup something today.

_______________________________________________________

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org

Check out our other podcasts here: https://investorconnect.org/
For Investors check out: https://tencapital.group/investor-landing/
For Startups check out: https://tencapital.group/company-landing/
For eGuides check out: https://tencapital.group/education/
For upcoming Events, check out https://tencapital.group/events/

For Feedback please contact info@tencapital.group

Please follow, share, and leave a review.

Music courtesy of Bensound.